Embedded Files
First-in-class RNA therapies targeting metabolic flux for obesity with no appetite suppression.
Idun Biologics Presentation Biostock Global Summit.mp4Company highlights:
• First-in-class target (G3PP).
• Differentiated MoA beyond existing obesity therapies.
• GWAS validation & in vivo POC.
• RNA platform for increased tolerance and convenience.
• Large and growing obesity market.
• Potential application in multiple TAs beyond obesity.
Page updated
Report abuse